Editas Medicine (EDIT) Earnings Analysis

Editas Medicine (EDIT) next reports earnings on 2026-08-11, consensus EPS -0.3 USD. Last quarter (2026-03-09) it beat with EPS -0.06 USD vs -0.27 USD est (+77.8%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -2.26.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does EDIT next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.3 USD
Revenue estimate0.00B

EDIT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-09-0.06 USD-0.27 USD+77.8%Beat
2025-11-10-0.28 USD-0.38 USD+26.3%Beat
2025-05-12-0.43 USD-0.51 USD+15.7%Beat
2025-03-05-0.55 USD-0.39 USD-41%Miss
2024-11-04-0.75 USD-0.76 USD+1.3%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

EDIT valuation and analyst view

Trailing P/E-2.26
Trailing EPS-1.11315 USD
Price / book61.73
Dividend yield0.00%
Market cap0.27B
Analyst consensusBuy (14 buy / 9 hold / 2 sell)
Avg price target4 USD

Related research pages

Frequently asked questions

When is Editas Medicine (EDIT)'s next earnings date?

Editas Medicine is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.3 USD and revenue estimate of 0.00B.

Did EDIT beat earnings last quarter?

In its 2026-03-09 report, EDIT posted EPS of -0.06 USD versus a -0.27 USD estimate — a beat of 77.8%.

What is EDIT's earnings track record?

Over the last 5 reported quarters with consensus data, EDIT beat estimates 4 times (80%).

What is EDIT's current P/E ratio and EPS?

EDIT trades at a trailing P/E of -2.26 on trailing EPS of -1.113146008754881 USD.

What do analysts rate EDIT?

Analyst consensus is "Buy" across 25 ratings (0 strong buy, 14 buy, 9 hold, 2 sell, 0 strong sell). Average 12-month price target: 4 USD.